Sillajen Appoints Kim Jae-kyung as New CEO: "Committed to Normalizing Trading and Restoring Shareholder Value"

Attorney Jang Yongjae and Professor Jeong Byeonguk Appointed Outside Directors
Strengthening Management Transparency Through Executive Restructuring

Kim Jae-kyung, the new CEO of SillaJen.

[Asia Economy Reporter Lee Gwan-ju] SillaJen has appointed a new CEO and is taking steps to normalize trading and strengthen management transparency.

On the 4th, SillaJen held an extraordinary general meeting of shareholders and a board meeting, announcing the appointment of CEO Kim Jae-kyung.

CEO Kim was a founding member and former CEO of LabGenomics, a genetic and molecular diagnostic testing company, and served as an adjunct professor in the Department of Psychiatry at Sungkyunkwan University School of Medicine.

Through this extraordinary general meeting, CEO Kim was appointed as a registered director of SillaJen and subsequently entrusted with the important role of CEO by the board.

CEO Kim stated, "I feel a heavy responsibility in taking on the role of SillaJen CEO at this critical time," adding, "I will do my best to normalize trading, strengthen management transparency, and restore shareholder value."

Alongside this, at the extraordinary general meeting, SillaJen appointed lawyer Jang Yong-jae from the law firm Kwangjang and Professor Jeong Byeong-wook of the University of Seoul as outside directors. Lawyer Jang is an international law expert who passed the bar exams in Australia and the United Kingdom and gained experience in international finance in Hong Kong. He is also a specialist committee member at the Korea Health Industry Development Institute and plans to focus on legal advisory and strengthening internal controls at SillaJen. Professor Jeong previously served as an associate professor in finance at Ewha Womans University and currently holds a professorship in finance at the University of Seoul.

Additionally, former auditor of the National Pension Service, Lee Young-woo, was appointed as a full-time auditor. The new outside directors and full-time auditor were recommended by the Korea Listed Companies Association and the KOSDAQ Committee.

A SillaJen official explained, "With this management restructuring, we have composed the internal directors with personnel from the pharmaceutical and bio sectors and reorganized the management with external outside directors to strengthen management transparency," adding, "This is a management restructuring that considers not only the resumption of trading but also the period thereafter as a research and development company."

This content was produced with the assistance of AI translation services.